Novartis strikes cardiovascular discovery deal with Flagship’s ProFound
Novartis has signed up proteomics specialist ProFound Therapeutics to pinpoint “previously unknown” proteins to be investigated as cardiovascular drugs and drug targets in a $25 million upfront deal. The four-year partnership could be quite the ...
Novartis has signed up proteomics specialist ProFound Therapeutics to pinpoint “previously unknown” proteins to be investigated as cardiovascular drugs and drug targets in a $25 million upfront deal.
The four-year partnership could be quite the ...
